Frequently Asked Questions
The market is segmented based on , By Type (Retinal Tear, Retinal Detachment, Diabetic Retinopathy, Macular Degeneration, Macular Hole, Others), Diagnosis (Digital fluorescein Angiography, Optical Coherence Tomography, Heidelberg Retinal Tomography, Indocyanine Green Angiography, Others), Treatment (Surgery, Medication, Others), Route of Administration (Oral, Parenteral, Ocular, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
.
The Global Vitreoretinal Disorders Market size was valued at USD 1.60 USD Billion in 2021.
The Global Vitreoretinal Disorders Market is projected to grow at a CAGR of 8% during the forecast period of 2022 to 2029.
The major players operating in the market include Aerie Pharmaceuticals,Allergan,Bausch Health,Merck & Co ,Pfizer ,Teva Pharmaceutical Industries Ltd,Amorphex Therapeutics Holdings ,Alcon,Astellas Pharma ,Bayer AG,Novartis AG,AstraZeneca,Amgen ,Carl Zeiss Meditec AG,HumanOptics Holding AG,STAAR SURGICAL.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
